On Nov 08, major Wall Street analysts update their ratings for $Jazz Pharmaceuticals (JAZZ.US)$, with price targets ranging from $130 to $230.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $140.
Barclays analyst Balaji Prasad maintains with a buy rating, and adjusts the target price from $200 to $190.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and adjusts the target price from $120 to $130.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $200 to $195.
Needham analyst Ami Fadia maintains with a buy rating, and maintains the target price at $207.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals reported third-quarter revenue in line with expectations and a considerable non-GAAP net income beat, despite facing short-term challenges affecting the Rylaze brand. Overall, the third-quarter results were deemed 'solid.' The company is perceived to be trading at significantly low multiples, while still promising mid-single digit revenue growth and high-single digit earnings growth on a compound annual basis.
Jazz Pharmaceuticals' third quarter revenue outperformance was propelled by robust growth in key products such as Xywav and Epidiolex. However, Rylaze experienced a temporary setback due to updates in the treatment protocol.
The firm noted that Jazz Pharmaceuticals' total Q3 revenue surpassed expectations, bolstered by strong performance from products such as Xywav, Epidiolex, Defitelio, and Zepzelca.
Here are the latest investment ratings and price targets for $Jazz Pharmaceuticals (JAZZ.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月8日，多家華爾街大行更新了$爵士製藥 (JAZZ.US)$的評級，目標價介於130美元至230美元。
摩根士丹利分析師Jeffrey Hung維持持有評級，維持目標價140美元。
巴克萊銀行分析師Balaji Prasad維持買入評級，並將目標價從200美元下調至190美元。
富國集團分析師Mohit Bansal維持持有評級，並將目標價從120美元上調至130美元。
TD Cowen分析師Joseph Thome維持買入評級，並將目標價從200美元下調至195美元。
Needham分析師Ami Fadia維持買入評級，維持目標價207美元。
此外，綜合報道，$爵士製藥 (JAZZ.US)$近期主要分析師觀點如下：
爵士製藥報告的第三季度營業收入符合預期，並且非通用會計淨利潤有較大增長，儘管面臨影響Rylaze品牌的短期挑戰。總體而言，第三季度的業績被認爲是"穩固"的。公司被認爲正以極低的倍數交易，同時在複合年度基礎上仍承諾中單位數的營收增長和高單位數的盈利增長。
爵士製藥的第三季度營收表現優異，得益於Xywav和Epidiolex等主要產品的強勁增長。然而，Rylaze由於治療方案更新遭遇了暫時的挫折。
公司指出，爵士製藥的整體第三季度營收超出預期，得益於Xywav、Epidiolex、Defitelio和Zepzelca等產品的強勁表現。
以下爲今日8位分析師對$爵士製藥 (JAZZ.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
